可注射的模仿血小板的丝蛋白-结合微球,用于调节血静和针对性治疗内部出血
Yajun Shuai1,2, Yu Qian1, Meidan Zheng1
1Institute of Applied Bioresource Research, College of Animal Sciences, Zhejiang University, Hangzhou, 310058, China.
Journal of nanobiotechnology
|February 20, 2025
概括
新的丝纤维蛋白微球模仿血小板,快速停止深度出血. 这些注射剂准创伤部位,迅速形成血块,副作用最小,改善血静.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 血液静止研究 血液静止研究
背景情况:
- 创伤造成的失控深度出血对患者的生存构成重大威胁.
- 开发有效的止血剂来治疗深层组织损伤仍然具有挑战性.
- 自然血小板启动快速血静,为人工药物提供了一个模型.
研究的目的:
- 在深层组织损伤中设计类似血小板的微球,以实现快速和有针对性的血液静止.
- 用丝纤维素和瘤向的来模仿自然的血小板功能.
- 在体内评估这些新型静血微球的疗效和生物相容性.
主要方法:
- 丝纤维素 (SF) 和针对血栓的酸被制成微球,使用冷自组装.
- 分析了微球特征 (大小,形状,泽塔潜力).
- 评估了细胞相容性,血液相容性和抗细胞粘附性.
- 在体内研究中评估了注射后的向,血静,降解和生物相容性.
主要成果:
- /SF微球在尺寸,形状和泽塔潜力方面模仿了天然血小板.
- 微球表现出有利的细胞相容性,血液相容性和抗细胞粘附性.
- 它们促进了纤维素聚合,血小板粘附和纤维素结合,模仿激活的血小板.
- 在体内,微球在5分钟内快速准出血部位,与单独的SF相比,减少了74%的出血量.
- 微球呈现出快速降解 (71%在1天内) 和出色的长期生物相容性与最小的炎症.
结论:
- 可注射的基于丝纤维素的静血微球有效地模仿天然血小板,以实现快速的静血.
- 这些微球表明,由于有针对性的输送和高效的血栓形成,这些微球有望治疗组织损伤的深度出血.
- 开发的止血剂为具有挑战性的出血情景提供了生物相容性和有效的解决方案.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
593
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
593
Formation of the Platelet Plug
3.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455
Introduction to Hemostasis
5.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.0K


